Myasthenia Gravis
Welcome,         Profile    Billing    Logout  
 64 Companies   21 Products   21 Products   23 Mechanisms of Action   207 Trials   10745 News 


«12...116117118119120121122123124125126...136137»
  • ||||||||||  batoclimab (IMVT-1401) / Roivant
    Trial completion date, Trial primary completion date:  A Study of RVT-1401 in Myasthenia Gravis (MG) Patients (clinicaltrials.gov) -  Jan 13, 2020   
    P2a,  N=21, Recruiting, 
    History of PMC, thymoma, generalized MG, bulbar symptom, and concomitant complication are the risk factors of PMC. Trial completion date: Feb 2020 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Aug 2020
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal, Adverse events:  Cascade of immunologic adverse events related to pembrolizumab treatment. (Pubmed Central) -  Jan 12, 2020   
    However, some adverse events, if not early recognised, could be life-threatening. We report a patient with non-small cell lung cancer who received treatment with pembrolizumab and developed multiple immune-related adverse events both during and after completing treatment, including rash, pericarditis, colitis and myasthenia gravis.
  • ||||||||||  Review, Journal:  The Muscle Is Not a Passive Target in Myasthenia Gravis. (Pubmed Central) -  Jan 12, 2020   
    Finally, the regenerative capacities of the MG muscle tissue may be altered. Altogether, the studies reported in this review demonstrate that the muscle is not a passive target in MG, but interacts dynamically with its environment in several ways, activating mechanisms of compensation that limit the pathogenic mechanisms of the autoantibodies.
  • ||||||||||  Journal:  Impact of autoimmune comorbidity on fatigue, sleepiness and mood in myasthenia gravis. (Pubmed Central) -  Jan 11, 2020   
    While many MG patients were affected by fatigue, sleepiness, depression and anxiety, the present study does not suggest that coexisting autoimmune diseases substantially contribute to the magnitude of these cumbersome comorbid symptoms. However, the higher frequency of steroid treatment may have counterbalanced the effects of the autoimmune comorbidity.
  • ||||||||||  Journal:  Validation of the Triple Timed Up-and-Go Test in Lambert-Eaton Myasthenia. (Pubmed Central) -  Jan 11, 2020   
    The 3TUG is reproducible, demonstrates construct validity for assessment of lower extremity function in LEM patients, and correlates with changes in patient and physician assessments. These findings, along with prior reliability studies, indicate 3TUG is a valid measure of disease severity in LEM.
  • ||||||||||  prednisone / Generic mfg.
    Clinical, Journal:  iTRAQ-Based Proteomics Analysis of Plasma of Myasthenia Gravis Patients Treated with Jia Wei Bu Zhong Yi Qi Decoction. (Pubmed Central) -  Jan 11, 2020   
    A proportion of MG patients did not get satisfactory results after treatment with pyridostigmine and prednisone...For instance, some key proteins such as C-reactive protein, apolipoprotein C-III, apolipoprotein A-II, alpha-actinin-1, and thrombospondin-1 have been found to be abnormally expressed in T3 group compared to T1 group or T2 group. Interaction network analyses also provided some potential biomarkers or targets for MG management.
  • ||||||||||  Retrospective data, Journal:  Subxiphoid uniportal VATS for thymic and combined mediastinal and pulmonary resections - A two year experience. (Pubmed Central) -  Jan 10, 2020   
    The excellent exposure of the anterior mediastinum, the possibility of conducting complex procedures, such as extended thymectomies and combined mediastinal and pulmonary resections with good results of minimal morbidity represent the strong points of this technique. Thoracic surgeons experienced in VATS can safely perform subxiphoid uniportal VATS for mediastinal surgery.
  • ||||||||||  Clinical, Review, Journal:  Systematic review of the clinical spectrum of CASPR2 antibody syndrome. (Pubmed Central) -  Jan 10, 2020   
    Other presentations include peripheral nerve hyperexcitability or Morvan syndromes, cerebellar syndromes, behavioral and cognitive changes, and more rarely movement disorders. The most commonly associated malignancy was thymoma and suggests a role for thymoma screening in CASPR2-related diseases.
  • ||||||||||  Clinical, Journal:  Clinical electrophysiology of muscle diseases and episodic muscle disorders. (Pubmed Central) -  Jan 8, 2020   
    The study of sensory nerve conduction should involve two to three nerves in order to disclose the coexistence of a sensory neuropathy (particularly in mitochondrial myopathies). If the diagnosis remains uncertain, functional provocative tests should be performed: 3Hz repetitive nerve stimulation to search for a myasthenic syndrome, repeated short exercise (combined with cooling if necessary) in the case of myotonic syndrome; long exercise test if periodic paralysis is suspected.
  • ||||||||||  Clinical, Journal:  Clinical neurophysiology of neuromuscular junction disease. (Pubmed Central) -  Jan 8, 2020   
    Motor unit potential (MUP) instability or jiggle is the main finding seen in NMJ disorders on conventional needle EMG and reflects the moment-to-moment variability in the number and synchrony of muscle fiber action potentials (MFAPs) that compose a MUP. Single fiber EMG (SFEMG) is a highly selective technique that assesses jitter, the temporal variability in MFAPs generated in response to motor nerve action potentials.
  • ||||||||||  Clinical, Journal:  The Value of CT and MRI for Determining Thymoma in Patients With Myasthenia Gravis. (Pubmed Central) -  Jan 8, 2020   
    When combining both qualitative and quantitative parameters, MRI had even higher accuracy than did CT in thymoma diagnosis (P = .031). In conclusion, chemical shift MRI was more accurate than CT for differentiating thymoma from nonthymoma in patients with MG.
  • ||||||||||  Clinical, Journal, IO Biomarker:  B Cell Immunophenotyping and Transcriptional Profiles of Memory B Cells in Patients with Myasthenia Gravis. (Pubmed Central) -  Jan 8, 2020   
    Herein, we investigated quantitative distribution of peripheral blood B cell subsets and transcriptional profiles of memory B cells (CD19+ CD27+) in several subgroups of MG patients classified according to the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification. This study suggests potential immunologic B-cell markers that may guide treatment decision in future clinical settings.
  • ||||||||||  mezagitamab (TAK-079) / Takeda
    Enrollment open:  A Study of TAK-079 in People With Generalized Myasthenia Gravis (clinicaltrials.gov) -  Jan 5, 2020   
    P2,  N=36, Recruiting, 
    Conclusions These findings put more insights into understanding the interaction of pectolinarin and AchE, as well as Alzheimer's disease. Not yet recruiting --> Recruiting
  • ||||||||||  KEARNS SAYRE SYNDROME - AN INTERESTING CASE REPORT () -  Jan 5, 2020 - Abstract #AIOC2020AIOC_957;    
    External examination revealed epicanthus with severe ptosis,Restricted extraocular movements with normal pupillary reactions.Fundus examination revealed pigmentary retinopathy.Orbicularis Oculi Muscle biopsy revealed "Ragged red fibres".Audiometry revealed sensorineural hearing loss.Cardiac evaluation revealed Left axis deviation and left ventricular hypertrophy.All key findings are photographically recorded.Chronic Progressive external ophthalmoplegia with ptosis and pigmentary retinopathy forms the triad of "Kearns sayres syndrome",a mitochondrial myopathy.Single muscle fibre electromyography ruled out myasthenia gravis in this case.Supportive multidisciplinary management with Ptosis and Refractory error correction is planned. This case is being reported for its rare incidence.
  • ||||||||||  KEARNS SAYRE SYNDROME - AN INTERESTING CASE REPORT () -  Jan 5, 2020 - Abstract #AIOC2020AIOC_951;    
    External examination revealed epicanthus with severe ptosis,Restricted extraocular movements with normal pupillary reactions.Fundus examination revealed pigmentary retinopathy.Orbicularis Oculi Muscle biopsy revealed "Ragged red fibres".Audiometry revealed sensorineural hearing loss.Cardiac evaluation revealed Left axis deviation and left ventricular hypertrophy.All key findings are photographically recorded.Chronic Progressive external ophthalmoplegia with ptosis and pigmentary retinopathy forms the triad of "Kearns sayres syndrome",a mitochondrial myopathy.Single muscle fibre electromyography ruled out myasthenia gravis in this case.Supportive multidisciplinary management with Ptosis and Refractory error correction is planned. This case is being reported for its rare incidence.
  • ||||||||||  Clinical, Journal:  Pattern of Habitual Physical Exercise in Myasthenia Gravis Patients. (Pubmed Central) -  Jan 4, 2020   
    Although a majority of MG patients meet the recommendations of deliberate exercise, their baseline physical activity levels are dominated by sedentary behavior. In comparison with a healthy population, MG patients are less physically active, but the reason for this remains unclear with no correlations between disease severity and physical activity patterns.
  • ||||||||||  Clinical, Journal, HEOR:  Healthcare resource utilization by patients with treatment-refractory myasthenia gravis in England. (Pubmed Central) -  Jan 4, 2020   
    In comparison with a healthy population, MG patients are less physically active, but the reason for this remains unclear with no correlations between disease severity and physical activity patterns. Patients in England with refractory MG more often visit healthcare providers, are hospitalized, and visit an emergency room than patients with non-refractory MG.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Review, Journal, HEOR:  Quality of life in refractory generalized myasthenia gravis: A rapid review of the literature. (Pubmed Central) -  Jan 1, 2020   
    This outcome is of great importance for the choice of therapeutic options in patients with refractory GMG. Eculizumab generates improvements in the perception of patients' quality of life compared to placebo, making it a relevant therapeutic option in the management of refractory GMG.
  • ||||||||||  Rituxan (rituximab) / Roche, Biogen
    Retrospective data, Journal:  Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study. (Pubmed Central) -  Jan 1, 2020   
    http://creativecommons.org/licenses/by-nc-nd/4.0/. In this small retrospective study, we used RTX as induction therapy and results suggest that repeated RTX infusions may not be necessary as it adds to cost of therapy, especially in LMIC like India.
  • ||||||||||  Journal:  Single fiber electromyography. (Pubmed Central) -  Jan 1, 2020   
    Normal jitter findings in a clinically weak muscle exclude neuromuscular junction disease as a cause for weakness in that muscle. FD measurements assess the local concentration of muscle fibers within a motor unit and provide a sensitive in vivo assessment of reinnervation.